504 related articles for article (PubMed ID: 12391241)
81. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
82. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
[TBL] [Abstract][Full Text] [Related]
83. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
Yi Q; Szmania S; Freeman J; Qian J; Rosen NA; Viswamitra S; Cottler-Fox M; Barlogie B; Tricot G; van Rhee F
Br J Haematol; 2010 Sep; 150(5):554-64. PubMed ID: 20618329
[TBL] [Abstract][Full Text] [Related]
84. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
85. Intratumoral immunotherapy for melanoma.
Singh M; Overwijk WW
Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
[TBL] [Abstract][Full Text] [Related]
86. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
[TBL] [Abstract][Full Text] [Related]
87. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
Neelapu SS; Baskar S; Kwak LW
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
[TBL] [Abstract][Full Text] [Related]
88. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity.
Lambert LA; Gibson GR; Maloney M; Durell B; Noelle RJ; Barth RJ
Cancer Res; 2001 Jan; 61(2):641-6. PubMed ID: 11212262
[TBL] [Abstract][Full Text] [Related]
89. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
[TBL] [Abstract][Full Text] [Related]
90. Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.
Zheng H; Liu L; Zhang H; Kan F; Wang S; Li Y; Tian H; Meng S
PLoS One; 2019; 14(1):e0211490. PubMed ID: 30703157
[TBL] [Abstract][Full Text] [Related]
91. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.
De Costa AM; Justis DN; Schuyler CA; Young MR
Int Immunopharmacol; 2012 Jul; 13(3):322-30. PubMed ID: 22609090
[TBL] [Abstract][Full Text] [Related]
92. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.
Franki SN; Steward KK; Betting DJ; Kafi K; Yamada RE; Timmerman JM
Blood; 2008 Feb; 111(3):1504-11. PubMed ID: 17993615
[TBL] [Abstract][Full Text] [Related]
93. Comparison of dendritic cell-mediated immune responses among canine malignant cells.
Tamura K; Arai H; Ueno E; Saito C; Yagihara H; Isotani M; Ono K; Washizu T; Bonkobara M
J Vet Med Sci; 2007 Sep; 69(9):925-30. PubMed ID: 17917377
[TBL] [Abstract][Full Text] [Related]
94. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen.
Gilliet M; Kleinhans M; Lantelme E; Schadendorf D; Burg G; Nestle FO
Blood; 2003 Jul; 102(1):36-42. PubMed ID: 12560234
[TBL] [Abstract][Full Text] [Related]
95. Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Sciullo PD; Menay F; Cocozza F; Gravisaco MJ; Waldner CI; Mongini C
Clin Immunol; 2019 Jun; 203():154-161. PubMed ID: 31048012
[TBL] [Abstract][Full Text] [Related]
96. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
97. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.
Barth RJ; Fisher DA; Wallace PK; Channon JY; Noelle RJ; Gui J; Ernstoff MS
Clin Cancer Res; 2010 Nov; 16(22):5548-56. PubMed ID: 20884622
[TBL] [Abstract][Full Text] [Related]
98. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.
Mitchell DA; Batich KA; Gunn MD; Huang MN; Sanchez-Perez L; Nair SK; Congdon KL; Reap EA; Archer GE; Desjardins A; Friedman AH; Friedman HS; Herndon JE; Coan A; McLendon RE; Reardon DA; Vredenburgh JJ; Bigner DD; Sampson JH
Nature; 2015 Mar; 519(7543):366-9. PubMed ID: 25762141
[TBL] [Abstract][Full Text] [Related]
99. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
100. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]